Omega Therapeutics (OMGAQ) Stock Price, News & Analysis

Company Overview

Omega Therapeutics, Inc. is a biotechnology company focused on developing medicines that regulate gene expression through epigenetic mechanisms. The company’s approach is based on the idea that gene activity can be selectively controlled without changing the underlying DNA sequence.

Omega developed its proprietary Omega Epigenomic Programming platform to create precision therapies known as Epigenomic Controllers. These investigational medicines are designed to target disease-related gene programs and have been explored in areas including oncology, autoimmune disease and other serious conditions. The company’s research programs have included OTX-2002, an investigational therapy aimed at regulating MYC-driven cancer biology, as well as additional preclinical and clinical-stage candidates.

Founded in 2016 and headquartered in Cambridge, Massachusetts, Omega Therapeutics conducted its research and development activities primarily in the United States. The company was associated with Flagship Pioneering and was led for several years by Mahesh Karande, who served as president and chief executive officer. Its programs remain investigational and are subject to clinical testing and regulatory review.

Key Stats

• Today's Range: $0.0030 to $0.0030
• 50-Day Range: N/A
• 52-Week Range: $0.00 to $1.69
• Volume: N/A
• Average Volume: 215,590 shs
• Market Capitalization: $166.10 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 8/06/2024
• Today: 9/28/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:OMGAQ
• Previous Symbol: NASDAQ:OMGA
• CIK: 1850838
• Web: www.omegatherapeutics.com
• Phone: 617-949-4360
• Fax: N/A
• Employees: 120
• Year Founded: 2017

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $3.09 million
• Price / Sales: 0.05
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.05 per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 55,366,000
• Free Float: 50,660,000
• Market Cap: $166.10 thousand
• Optionable: No Data
• Beta: 0.57